UK NICE Says Yes To Vizimpro & Libtayo But Rejects Tagrisso
Executive Summary
Pfizer and AstraZeneca were seeking National Health Service funding for the same indication for their respective lung cancer drugs. With "responsible pricing" after an initial rejection, Pfizer prevailed.